Unco therapeutics awarded the abbVie golden ticket

Unco Therapeutics was awarded the AbbVie Golden Ticket following a competitive selection process across the U.S. and Europe. The award recognizes early-stage biotech companies developing innovative therapeutics in migraine and provides one year of fully funded lab and office space at BioLabs @ NYU Langone, along with access to AbbVie’s scientific and strategic expertise. This recognition marks a key milestone for Unco Therapeutics, supporting continued advancement of its therapeutic pipeline.